SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is experiencing significant volatility and heightened trading activity as the market aggressively reprices storage stocks amid intense AI-driven infrastructure demand. The community is actively debating whether this movement represents a structural, long-term supercycle in memory and storage or an overextended speculative bubble driven by retail FOMO and institutional rotation.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense social media debate, driven by institutional adoption concerns and speculation regarding the sustainability of corporate holding strategies. The community is sharply divided, with bearish voices highlighting macroeconomic pressures and technical chart patterns, while bullish proponents view the current price action as an accumulation opportunity and a necessary correction before potential future gains.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs remains a focal point for investors as they monitor high steel pricing against ongoing debt concerns and the high-stakes potential of a strategic partnership with POSCO. Community sentiment is deeply divided, with many traders debating whether the stock is an undervalued infrastructure play linked to AI-driven demand or a high-risk asset hampered by corporate leadership.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan is currently trending as investors weigh recent leadership succession updates and bank dividend hikes against a broader rotation in the financials sector. The community is actively discussing the bank's long-term capital strategy, its potential for major acquisitions, and its role as a defensive anchor amidst ongoing market volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors engage in intense speculation and debate regarding potential Russell 1000 index inclusion, fueling high options activity and volatility. The community remains divided, with bulls emphasizing long-term growth catalysts like ANKTIVA and global expansion, while others warn of market manipulation and potential pullbacks following the rebalancing.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is experiencing intense volatility as investors debate whether the recent surge to all-time highs marks a sustainable breakout or a bull trap. Market participants are closely watching technical indicators and the potential for a sharp pullback, even as community sentiment remains divided between long-term confidence in AI data infrastructure demand and concerns over a possible technical correction.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending following its recent integration with MetaMask Mobile and the launch of a new savings app designed to compete with traditional banking, fueling community optimism around its long-term growth. Investors are actively discussing the protocol's protocol revenue, potential for institutional RWA adoption, and its comparative valuation against DeFi rivals.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors speculate on a major buyout and a potential short squeeze, fueled by record short interest and intense community focus on the stock's upward momentum. Discussion is heavily concentrated on the extreme pressure building on short sellers to cover their positions as the community anticipates imminent clinical trial catalysts.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is trending as the community debates a potential rebound fueled by the return of NBCUniversal channels and excitement surrounding the FIFA World Cup. While bulls point to these catalysts and institutional price targets as signs of a turnaround, bears remain focused on historical share price declines, insider selling, and ongoing skepticism regarding the company's long-term profitability.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is seeing heightened activity as market participants closely watch the regulatory outcome for RGX-121 following recent safety concerns and a clinical hold. The community is actively debating the potential for a complete response letter versus a delayed decision, while many are also analyzing the company's cash position and the strategic implications of its partnership with AbbVie for the broader retinal program.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on top names. See analyst rating changes for PepsiCo, Octave Intelligence, Fervo Energy, Avalo Therapeutics, and Keurig Dr Pepper.read more...

Biotech Stocks To Add to Your Watchlist - May 6th

Danaher, Avalo Therapeutics, Vertex Pharmaceuticals, United Therapeutics, argenex, ImmunityBio, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science and technology t...

Avalo Therapeutics (NASDAQ:AVTX) Reaches New 1-Year High Following Analyst Upgrade

Avalo Therapeutics (NASDAQ:AVTX) Sets New 52-Week High Following Analyst Upgrade...

Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $58.00

BTIG Research upped their target price on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a 'buy' rating in a research report on Wednesday...

This Small-Cap Biotech Stock Is Tracking A Crucial Bullish Technical Milestone – And Retail Traders Are Taking Notice

Equity

Avalo Therapeutics announced a $375 million capital raise following a positive Phase 2 trial for skin inflammation treatment.

Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why

Avalo Therapeutics Inc. rises sharply in pre-market trading following a Phase 2 trial win and a $375 million offering.read more...

AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results 

Avalo was evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa across two dosing regimens.


Avalo Therapeutics (AVTX) to Release Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-avalo-therapeutics-inc-stock...

Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $111,886.11 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,457 shares of the company's stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the...

Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$18.20
Prev Close	$18.00
Open	$18.29
Dividend Yield	0.00%
50-Day Moving Average	$15.76
Beta	1.68
Avg. Volume	2.93M
PE Ratio	-3.09

52-Week High	$24.27
52-Week Low	$4.55
Market Capitalization	$946.18M
EPS (Annual)	-$5.84
Price to Book	6.49
Revenue Per Employee	$1,787.88

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVTXAvalo Therapeutics Inc

Latest AVTX News